Results 111 to 120 of about 939 (187)
Migraine overview and summary of current and emerging treatment options
, 2019 Migraine is a leading cause of disability worldwide. Approximately 15% of Americans experience migraines. Most people who have migraines feel that people who do not have them often underestimate their condition.
Peters, Golden L
core +1 more source
Asymmetric Synthesis of Chiral δ-Caprolactams: Access to a Key Intermediate of Ubrogepant
Chiral δ-caprolactam constitutes the key pharmacophore of Calcitonin gene-related peptide receptor antagonists such as ubrogepant and atogepant, and its synthesis is quite challenging.
Xuan Chen +7 more
core +1 more source
Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents. [PDF]
Curr Pain Headache RepShin L, Moon R, Gelfand A.
europepmc +1 more source
Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]
HeadacheLipton RB +4 more
europepmc +1 more source
Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population. [PDF]
Fed PractForrest A, Billow D, Martin A.
europepmc +1 more source
A Human Mass Balance and Metabolism Study of [<sup>14</sup>C]-Ubrogepant in Healthy Male Adults. [PDF]
Clin Pharmacol Drug DevBoinpally RR +13 more
europepmc +1 more source